IP Verse

Multiplex Pcr Detection Of Alk, Ret, And Ros Fusions - EP3631011

The patent EP3631011 was granted to F Hoffmann LA Roche on Jun 23, 2021. The application was originally filed on May 30, 2018 under application number EP18730279A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3631011

F HOFFMANN LA ROCHE
Application Number
EP18730279A
Filing Date
May 30, 2018
Status
Granted And Under Opposition
May 21, 2021
Publication Date
Jun 23, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

STRAWMANMar 22, 2022HOFFMANN EITLEADMISSIBLE

Patent Citations (22) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS5674738
INTERNATIONAL-SEARCH-REPORTCN104818320
INTERNATIONAL-SEARCH-REPORTUS2015315657
INTERNATIONAL-SEARCH-REPORTWO2014144121
INTERNATIONAL-SEARCH-REPORTWO2016166269
OPPOSITIONCN104818320
OPPOSITIONEP2971093
OPPOSITIONEP3123380
OPPOSITIONUS2013102006
OPPOSITIONUS2014288116
OPPOSITIONUS2015315657
OPPOSITIONUS2018346994
OPPOSITIONWO2004099434
OPPOSITIONWO2014144121
OPPOSITIONWO2014150300
OPPOSITIONWO2015148494
OPPOSITIONWO2015149034
OPPOSITIONWO2016166269
OTHERCN104818320
OTHERWO2014150300
OTHERWO2015148494
OTHERWO2015149034

Non-Patent Literature (NPL) Citations (50) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- CARDULLO et al., Proc. Natl. Acad. Sci. USA, (19880000), vol. 85, page 8790
DESCRIPTION- FAKRUDDIN et al., J Pharm Bioallied Sci., (20130000), vol. 5, page 245
DESCRIPTION- GASPARIC et al., Anal. Bioanal. Chem., (20100000), vol. 396, page 2023
DESCRIPTION- HOCHSTRASSER et al., Biophysical Chemistry, (19920000), vol. 45, page 133
DESCRIPTION- JOHANSSON, Meth. Mol. Biol., (20030000), vol. 335, page 17
DESCRIPTION- KAMISANGO et al., Clin. Microbiol., (19990000), vol. 37, page 310
DESCRIPTION- LIU et al., PLoSOne, (20150000), vol. 10, page eO117032
DESCRIPTION- MATSUBARA et al., Thorac. Oncol., (20070000), vol. 7, page 1872
DESCRIPTION- MOLOGNI, Curr. Med. Chem., (20110000), vol. 18, page 162
DESCRIPTION- NOWELL; HUNGERFORD, /. Natl. Cancer Inst., (19600000), vol. 25, page 85
DESCRIPTION- PFAFFL, Methods: The ongoing evolution of qPCR, (20100000), vol. 50
DESCRIPTION- PRESNER; CHINNAIYAN, Curr. Opin Genet. Dev., (20090000), vol. 19, page 82
DESCRIPTION- SELVIN, Methods in Enzymology, (19950000), vol. 246, page 300
DESCRIPTION- STEINBERG, Ann. Rev. Biochem., (19710000), vol. 40, pages 83 - 114
DESCRIPTION- VAN DEURSEN et al., Nucl. Acids Res., (19990000), vol. 27, page e15
DESCRIPTION- WANG et al., Anal. Chem., (19950000), vol. 67, pages 1197 - 1203
DESCRIPTION- YOSHIHARA et al., Oncogene, (20150000), vol. 34, page 4845
INTERNATIONAL-SEARCH-REPORT- MARUJA E. LIRA ET AL, "A Single-Tube Multiplexed Assay for Detecting ALK, ROS1, and RET Fusions in Lung Cancer", JOURNAL OF MOLECULAR DIAGNOSTICS,THE, US, (20140301), vol. 16, no. 2, doi:10.1016/j.jmoldx.2013.11.007, ISSN 1525-1578, pages 229 - 243, XP055280268 [A] 1-31 * the whole document *
INTERNATIONAL-SEARCH-REPORT- TONI-MAREE ROGERS ET AL, "Multiplexed transcriptome analysis to detect ALK, ROS1 and RET rearrangements in lung cancer", SCIENTIFIC REPORTS, (20170209), vol. 7, no. 1, doi:10.1038/srep42259, XP055498617 [A] 1-31 * the whole document *
INTERNATIONAL-SEARCH-REPORT- ISAMU OKAMOTO ET AL, "Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study", ONCOTARGET, United States, (20140430), vol. 5, no. 8, doi:10.18632/oncotarget.1906, ISSN 1949-2553, XP055498814 [A] 1-31 * page 2294, column 2, paragraph 2 * * page 2297, column 2, paragraph 3 *
OPPOSITION- Anonymous, "AmoyDx EML4-ALK Fusion gene detection kit", Amoy Diagnostics - Instruction for use, (20140701), pages 1 - 8, Amoy Diagnostics - Instruction for use, (20220405), XP055909180
OPPOSITION- Anonymous, "AmoyDx RET gene fusions detection kit", Amoy Diagnostics - Instruction for use, (20150701), pages 1 - 6, Amoy Diagnostics - Instruction for use, (20220405), XP055909173
OPPOSITION- Anonymous, "cobas@ EGFR Mutation Test v2", Roche Molecular Systems, (20150101), Roche Molecular Systems, URL: https://www.accessdata.fda.gov/cdrh_docs/pdf12/P120019S007c.pdf, (20220405), XP055909197
OPPOSITION- Anonymous, "Critical Factors for Successful Real-Time PCR", Real-Time PCR Brochure 07/2010, Qiagen, Real-Time PCR Brochure 07/2010, URL: https://www.gene-quantification.de/qiagen-qpcr-sample-assay-tech-guide-2010.pdf, (20201112), XP055749716
OPPOSITION- Anonymous, "The Archer™ Solution. A New Frontier in Fusion Detection", Enzymatics - Brochure, (20140101), pages 1 - 4, Enzymatics - Brochure, URL: http://www.enzymatics.com/wp-content/uploads/2014/01/Archer_Brochure_2014.pdf, (20220405), XP055909247
OPPOSITION- BLACK et al., "NSCLC: An update of driver mutations, their role in pathogenesis and clinical significance", R I Med J, (20151001), vol. 98, no. 10, pages 25 - 8, XP055883015
OPPOSITION- HITOSHI ICHIKAWA, "Clinical sequencing using an original cancer gene panel in National Cancer Center", Research & Clinical Trial Center, (20140607), vol. 249, no. 10, pages 1139 - 1144, XP055909222
OPPOSITION- PETER M et al., "A multiplex real-time per assay for the detection of gene fusions observed in solid tumors", Lab Invest, (20010600), vol. 81, no. 6, pages 905 - 12, XP002985561
OPPOSITION- BUBENDORF L et al., "Testing for ROS1 in non-small cell lung cancer: a review with recommendations", Virchows Arch, (20161100), vol. 469, no. 5, doi:10.1007/s00428-016-2000-3, pages 489 - 503, XP036084887
OPPOSITION- LIRA ME et al., "A Single-Tube Multiplexed Assay for Detecting ALK, ROS1, and RET Fusions in Lung Cancer. 2014", The Journal of Molecular Diagnostics, vol. 16, no. 2, doi:10.1016/j.jmoldx.2013.11.007, pages 229 - 243, XP055280268
OPPOSITION- Sunami Kuniko, Furuta Koh, Tsuta Koji, Sasada Shinji, Izumo Takehiro, Nakaoku Takashi, Shimada Yoko, Saito Motonobu, Nokihara Hiroshi, Watanabe Shun-Ichi, Ohe Yuichiro, Kohno Takashi, "Multiplex Diagnosis of Oncogenic Fusion and MET Exon Skipping by Molecular Counting Using Formalin-Fixed Paraffin Embedded Lung Adenocarcinoma Tissues", Journal of Thoracic Oncology, Elsevier Inc., US, US , (20160201), vol. 11, no. 2, doi:10.1016/j.jtho.2015.10.005, ISSN 1556-0864, pages 203 - 212, XP055909234
OPPOSITION- ZHAO C et al., "Detecting ALK, ROS1 and RET Fusion Genes in Cell Block Samples", Transl Oncol, (20140617), vol. 7, no. 3, doi:10.1016/j.tranon.2014.04.013, pages 363 - 7, XP055498635
OPPOSITION- DERVEAUX S et al., "How to do successful gene expression analysis using real-time PCR", Methods, (20100400), vol. 50, no. 4, doi:10.1016/j.ymeth.2009.11.001, pages 227 - 30, XP026941713
OPPOSITION- Camidge D Ross, Bang Yung-Jue, Kwak Eunice L, Iafrate A John, Varella-Garcia Marileila, Fox Stephen B, Riely Gregory J, Solomon Benjamin, Ou Sai-Hong I, Kim Dong-Wan, Salgia Ravi, Fidias Panagiotis, Engelman Jeffrey A, Gandhi Leena, Jänne Pasi A, Costa Daniel B, Shapiro Geoffrey I, Lorusso Patricia, Ruffner Katherine, Stephenson Patricia, Tang Yiyun, Wilner Keith, Clark Jeffrey W, Shaw Alice T, "Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study", The Lancet Oncology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20121001), vol. 13, no. 10, doi:10.1016/S1470-2045(12)70344-3, ISSN 1470-2045, pages 1011 - 1019, XP055909189
OPPOSITION- TAKEUCHI K et al., "RET, ROS1 and ALK fusions in lung cance r", Nat Med, (20120212), vol. 18, no. 3, doi:10.1038/nm.2658, pages 378 - 81, XP037532160
OPPOSITION- Toni-Maree Rogers, Gisela Mir Arnau, Georgina L. Ryland, Stephen Huang, Maruja E. Lira, Yvette Emmanuel, Omar D. Perez, Darryl Irwin, Andrew P. Fellowes, Stephen Q. Wong, Stephen B. Fox, "Multiplexed transcriptome analysis to detect ALK, ROS1 and RET rearrangements in lung cancer", Scientific Reports, (20171201), vol. 7, no. 1, doi:10.1038/srep42259, XP055498617
OPPOSITION- KWAK EL et al., "Anaplastic lymphoma kinase inhibition in non-small- cell lung cancer", N Engl J Med, (20101028), vol. 363, no. 18, doi:10.1056/NEJMoa1006448, pages 1693 - 703, XP055081495
OPPOSITION- Sequist L.V., Heist R.S., Shaw A.T., Fidias P., Rosovsky R., Temel J.S., Lennes I.T., Digumarthy S., Waltman B.A., Bast E., Tammireddy S., Morrissey L., Muzikansky A., Goldberg S.B., Gainor J., Channick C.L., Wain J.C., Gaissert H., Donahue D.M., Muniappan A., Wright C., Willers H., Mathisen D.J., Choi N.C., Baselga J., Lynch T.J., Ellisen L.W., Mino-Kenudson M., Lanuti M., Borger D.R., Iafrate A.J., Engelman J.A., Dias-Santagata D., "Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice", Annals of Oncology, Kluwer Dordrecht, NL, NL , (20111201), vol. 22, no. 12, doi:10.1093/annonc/mdr489, ISSN 0923-7534, pages 2616 - 2624, XP055909186
OPPOSITION- Motonobu Saito, "Gene aberrations for precision medicine against lung adenocarcinoma", CANCER SCIENCE, JAPANESE CANCER ASSOCIATION, TOKYO, JP, JP , (20160601), vol. 107, no. 6, doi:10.1111/cas.12941, ISSN 1347-9032, pages 713 - 720, XP093155691
OPPOSITION- DRILON A et al., "Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas", Cancer Discov, (20130600), vol. 3, no. 6, doi:10.1158/2159-8290.CD-13-0035, pages 630 - 5, XP055195155
OPPOSITION- Zheng Li-Mou, Whyte David B., Ruan Li, Song Roman, Fei Luo, Yang Nancy, Zhou Caicun, "Screening of NSCLC samples from Chinese lung cancer patients for activating rearrangements of the ALK, RET , and ROS1 genes.", Journal of Clinical Oncology, American Society of Clinical Oncology, US, US , (20130520), vol. 31, no. 15_suppl, doi:10.1200/jco.2013.31.15_suppl.e22066, ISSN 0732-183X, pages e22066 - e22066, XP055909193
OPPOSITION- LI C et al., "Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers", PLoS One, (20110000), vol. 6, no. 11, doi:10.1371/journal.pone.0028204, page e28204, XP055209333
OPPOSITION- Inoue Yoshiaki, Shiihara Jun, Miyazawa Hitoshi, Ohta Hiromitsu, Higo Megumi, Nagai Yoshiaki, Kobayashi Kunihiko, Saijo Yasuo, Tsuchida Masanori, Nakayama Mitsuo, Hagiwara Koichi, "A highly specific and sensitive massive parallel sequencer-based test for somatic mutations in non-small cell lung cancer", PLOS ONE, (20170427), vol. 12, no. 4, doi:10.1371/journal.pone.0176525, page e0176525, XP055909235
OPPOSITION- Reguart Noemí, Teixidó Cristina, Giménez-Capitán Ana, Paré Laia, Galván Patricia, Viteri Santiago, Rodríguez Sonia, Peg Vicente, Aldeguer Erika, Viñolas Nuria, Remon Jordi, Karachaliou Niki, Conde Esther, Lopez-Rios Fernando, Nadal Ernest, Merkelbach-Bruse Sabine, Büttner Reinhard, Rosell Rafael, Molina-Vila Miguel A, Prat Aleix, "Identification of ALK, ROS1, and RET Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non-Small-Cell Lung Cancer Patients", Clinical Chemistry, Oxford University Press, US, US , (20170301), vol. 63, no. 3, doi:10.1373/clinchem.2016.265314, ISSN 0009-9147, pages 751 - 760, XP055909237
OPPOSITION- OKAMOTO I et al., "Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study", Oncotarget, (20140430), vol. 5, no. 8, doi:10.18632/oncotarget.1906, pages 2293 - 304, XP055498814
OPPOSITION- VanGuilder H D; Vrana K E; Freeman W M, "Twenty-five years of quantitative PCR for gene expression analysis", Biotechniques, Informa Healthcare, US, US , (20080401), vol. 44, no. 5, doi:10.2144/000112776, ISSN 0736-6205, pages 619 - 626, XP001537018
OPPOSITION- Beyond, "Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer", Transl Lung Cancer Res, vol. 4, no. 2, doi:10.3978/j.issn.2218-6751.2014.11.11, (20150101), pages 156 - 164, Transl Lung Cancer Res, URL: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4384213/pdf/tlcr-04-02-156.pdf, XP055240876
OPPOSITION- KHOO C et al., "Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyond. 2015", Transl Lung Cancer Res, vol. 4, no. 2, doi:10.3978/j.issn.2218-6751.2015.01.10, pages 126 - 141, XP055799240
OTHER- Takashi Kohno et al, "Beyond ALK-RET, ROS1 and other oncogene fusions in lungcancer", Translational lung cancer research, (20150401), vol. 4, no. 2, pages 156 - 164, XP055240876
OTHER- Khoo C. et al, "Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyond", (20150401), vol. 4, no. 2, pages 126 - 141, XP055799240

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents